Fig. 1.

Amiloride alleviated cachexia progression in the CT26 murine model. a, b Body weight and tumor volume growth curves of the mice during the processes of establishing the animal models. c–h Characterization of cachexia features in the mice on day 30 ( = 6-8). c, d Tumor weights and tumor-free body weights of the mice. e Hindlimb muscle weights normalized to tibia length. f Gastrocnemius weights normalized to tibia length. g Soleus weights normalized to tibia length. h Grip strengths normalized to bodyweight. Statistical significances: p > 0.05, NS; p < 0.05, *; p < 0.01, **; p < 0.001, ***. NOR, C57BL/6 or BALB/c normal control mice; CAC, CT26 cachexia mice; AM, amiloride-treated mice; KD, mice inoculated with Rab27-knockdown CT26 cells